RCS - Angle PLC - ANGLE launches Portrait+ CTC kit at SABCS

AngleAnnouncement

05/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231205:nRSE6311Va&default-theme=true

RNS Number : 6311V  Angle PLC  05 December 2023

 For immediate release  5 December 2023

 

ANGLE plc ("the Company")

 

ANGLE LAUNCHES PORTRAIT+ CTC KIT AT San Antonio Breast Cancer Symposium

 

ANGLE's Portrait+ CTC staining kit combines the power of Parsortix(®)
technology with an optimised immunofluorescent assay

 

 The test is designed for highly accurate, repeatable, and precise results
allowing CTC identification, characterisation and enumeration

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is delighted to announce the
launch of its Portrait(®)+ CTC staining kit at the San Antonio Breast Cancer
Symposium (SABCS).

 

The Portrait+ CTC staining kit is a ready-to-use kit for the identification,
characterisation and enumeration of epithelial and mesenchymal cancer cells
including those undergoing epithelial-to-mesenchymal transition (EMT). EMT is
a key transition step in cancer cells, and is associated with tumour
progression, the development of drug resistance, and metastasis.

 

This launch follows extensive development, optimisation and validation of the
kit to provide advanced immunofluorescent (IF) staining of CTCs harvested from
a patient blood sample by the Parsortix technology. The performance of current
CTC protocols being used by academic and research institutions varies
considerably. ANGLE has developed its test for reliable repeatable results
with a fully validated, standardised protocol to make it easy for customers to
adopt. Key features of the product include:

 

·    use of a direct staining technique and an optimised, vivid dye
combination to ensure high signal intensity while maintaining high analytical
specificity and sensitivity

 

·    pre-mixed and freeze-dried antibodies for ease-of-use and long-term
storage

 

·    inclusion of a CellKeep™ slide, a unique CTC harvesting technology
developed by ANGLE to maximise the retention of CTCs harvested from blood
samples for imaging. The slide confines the harvested CTCs to a small area,
reducing the volume of antibodies required for staining, decreasing imaging
time and cost and minimising cell loss between the Parsortix system and the
imaging process.

 

It is well established that the number of CTCs is not only prognostic to
overall survival, but can monitor drug treatment response, detect early
development of (micro)metastases and assess therapeutic response earlier than
traditional imaging methods.

 

The Portrait+ CTC staining kit can be used to enumerate CTCs harvested using
the epitope independent Parsortix technology in multiple cancer types
including breast, lung, prostate and ovarian cancers.

 

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"ANGLE's Portrait+ CTC staining kit provides investigators with accurate,
repeatable, and precise identification of CTCs and hence has the potential to
optimise study protocols and minimise cost.

 

We are now beginning an active promotion of this test to academic and
translational research customers. The standardisation and simplification of
the cell staining process and the new innovations to retain the harvested
cells on the microscope slide will expand the market for Parsortix technology
as it will make it easier for customers to adopt the solution in their own
laboratories."

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)      +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratory in the UK.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRATIBRTMTAMBLJ